Northwest presses on with DCVax brain cancer trial
This article was originally published in Scrip
Executive Summary
Northwest Biotherapeutics is pressing ahead with enrolment into its ongoing large Phase II study of its personalised immune therapy for brain cancer DCVax-Brain.